Find, compare & contact
Lidoflazine API Manufacturers & Suppliers

teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Lidoflazine is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Lidoflazine or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Lidoflazine API 3416-26-0?

Description:
Here you will find a list of producers, manufacturers and distributors of Lidoflazine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Lidoflazine 
Synonyms:
Lidoflazina , Lidoflazinum  
Cas Number:
3416-26-0 
DrugBank number:
DB13766 
Unique Ingredient Identifier:
J4ZHN3HBTE

General Description:

Lidoflazine is a chemical compound identified by the CAS number 3416-26-0. It is known for its distinct pharmacological properties and applications.

Classification:

Lidoflazine belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups, classified under the direct parent group Diphenylmethanes. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the Diphenylmethanes subclass.

Categories:

Lidoflazine is categorized under the following therapeutic classes: Agents causing hyperkalemia, Antiarrhythmic agents, Bradycardia-Causing Agents, Calcium Channel Blockers, Calcium-Regulating Hormones and Agents, Cardiovascular Agents, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, Membrane Transport Modulators, Negative Inotrope, Non-Selective Calcium Channel Blockers, Piperazines, Potential QTc-Prolonging Agents, QTc Prolonging Agents, Vasodilating Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Lidoflazine is a type of Other calcium Channel Blockers


Other calcium channel blockers are a category of pharmaceutical active pharmaceutical ingredients (APIs) that work by inhibiting the influx of calcium ions into cells through voltage-gated calcium channels. These medications are primarily used to treat various cardiovascular conditions, such as hypertension (high blood pressure) and angina (chest pain).

Unlike commonly known calcium channel blockers like dihydropyridines and non-dihydropyridines, other calcium channel blockers encompass a diverse group of drugs that possess calcium channel-blocking activity but may have different chemical structures and mechanisms of action.

These APIs exert their therapeutic effects by binding to specific calcium channels in cardiac and smooth muscle cells, reducing calcium entry and subsequent muscle contraction. By doing so, they relax blood vessels, improve blood flow, and reduce cardiac workload, resulting in lower blood pressure and alleviation of angina symptoms.

Some examples of other calcium channel blockers include bepridil, mibefradil, and verapamil. These drugs may have additional effects beyond calcium channel blockade, such as antiarrhythmic properties or interactions with other receptor systems.

As with any medication, other calcium channel blockers may have potential side effects, including dizziness, flushing, constipation, and peripheral edema. Therefore, it is important to use these drugs under the supervision of a healthcare professional and follow the prescribed dosage instructions.

In conclusion, other calcium channel blockers are a diverse class of pharmaceutical APIs that act by blocking calcium channels, leading to decreased blood pressure and relief from angina. These medications offer an alternative treatment option for cardiovascular conditions and should be used as directed by a healthcare provider to ensure safety and efficacy.